Windmill Cardiovascular Systems has developed a new pumping paradigm to deliver synchronous, pulsatile, low-shear flow to support patients
with end-stage heart failure. The Toroidal Ventricular Assist Device (TORVAD) has the potential to reduce the high adverse event rates associated with
current VADs, which could improve the survival and quality of life for patients.
Company’s Keywords:
biotechnology, life sciences
<8
<
<
Your request has been submitted successfully.
Own or work here?